Lifecore Biomedical, Inc.
LFCRHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 3
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the. At a $164.7M market cap, Lifecore Biomedical, Inc. ranks as a micro-cap company within healthcare. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Market Cap
$164.7M
Beta
1.09
P/E (TTM)
—
P/E (Fwd)
-5.58
EPS (TTM)
$-1.17
EPS (Fwd)
$-0.78
ROE
—
ROA
—
Cash
$17.2M
Total Debt
$156.4M
Free CF
—
52W Change
-37.0%
Annual Financials
Cash vs Debt
Where LFCR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LFCR finished 10.73% below its 150-day moving average ($5.31) and 20.60% below its 200-day moving average ($5.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFCR overbought or oversold?
At the September 3, 2026 close, LFCR's RSI(14) was 50.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lifecore Biomedical, Inc. carries $156.4M in total debt against $17.2M in cash reserves — debt is roughly 9.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Revenue has been uneven over recent years, ranging from $111.3M to $128.9M.
Lifecore Biomedical, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LFCR.